 |
|
Targeting Behavioral Therapies to Enhance Naltrexone Treatment of Opioid Dependence
Efficacy of Contingency Management and Significant Other Involvement
Kathleen M. Carroll, PhD;
Samuel A. Ball, PhD;
Charla Nich, MS;
Patrick G. O'Connor, MD, MPH;
Dorothy A. Eagan, RN, MPH;
Tami L. Frankforter;
Elisa G. Triffleman, MD;
Julia Shi, MD;
Bruce J. Rounsaville, MD
Arch Gen Psychiatry. 2001;58:755-761.
Background Contingency management (CM) and significant other involvement (SO) were
evaluated as strategies to enhance treatment retention, medication compliance,
and outcome for naltrexone treatment of opioid dependence.
Methods One hundred twenty-seven recently detoxified opioid-dependent individuals
were randomly assigned to 1 of 3 conditions delivered for 12 weeks: (1) standard
naltrexone treatment, given 3 times a week; (2) naltrexone treatment plus
contingency management (CM), with delivery of vouchers contingent on naltrexone
compliance and drug-free urine specimens; or (3) naltrexone treatment, CM,
plus significant other involvement (SO), where a family member was invited
to participate in up to 6 family counseling sessions. Principal outcomes were
retention in treatment, compliance with naltrexone therapy, and number of
drug-free urine specimens.
Results First, CM was associated with significant improvements in treatment
retention (7.4 vs 5.6 weeks; P = .05) and in reduction
in opioid use (19 vs 14 opioid-free urine specimens; P
= .04) compared with standard naltrexone treatment. Second, assignment to
SO did not significantly improve retention, compliance, or substance abuse
outcomes compared with CM. Significant effects for the SO condition over CM
on retention, compliance, and drug use outcomes were seen only for the subgroup
who attended at least 1 family counseling session. The SO condition was associated
with significant (P = .02) improvements in family
functioning.
Conclusion Behavioral therapies, such as CM, can be targeted to address weaknesses
of specific pharmacotherapies, such as noncompliance, and thus can play a
substantial role in broadening the utility of available pharmacotherapies.
From the Department of Psychiatry, Yale University School of Medicine,
New Haven, Conn. Dr Triffleman is now with the S3 Project, Oakland, Calif.
Corresponding author and reprints: Kathleen M. Carroll, PhD, Department
of Psychiatry, Yale University School of Medicine,, VA CT Healthcare System,
950 Campbell Ave (151D), West Haven, CT 06516 (e-mail: kathleen.carroll{at}yale.edu).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A Meta-Analytic Review of Psychosocial Interventions for Substance Use Disorders
Dutra et al.
Am. J. Psychiatry 2008;165:179-187.
ABSTRACT
| FULL TEXT
A Stepped Care Strategy Using Buprenorphine and Methadone Versus Conventional Methadone Maintenance in Heroin Dependence: A Randomized Controlled Trial
Kakko et al.
Am. J. Psychiatry 2007;164:797-803.
ABSTRACT
| FULL TEXT
Results of Random Drug Testing in an Adolescent Substance Abuse Program
Levy et al.
Pediatrics 2007;119:e843-e848.
ABSTRACT
| FULL TEXT
Clinical Advances in Pharmacological and Integrated Treatment Approaches for Alcohol and Drug Use Disorders
Dermatis and Galanter
Focus 2007;5:141-150.
ABSTRACT
| FULL TEXT
Behavioral Therapies for Drug Abuse
Carroll and Onken
Focus 2007;5:240-248.
ABSTRACT
| FULL TEXT
HAART Adherence Strategies for Methadone Clients Who Are HIV-Positive: A Treatment Manual for Implementing Contingency Management and Medication Coaching.
Haug et al.
Behav Modif 2006;30:752-781.
ABSTRACT
Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes.
Sinha et al.
Arch Gen Psychiatry 2006;63:324-331.
ABSTRACT
| FULL TEXT
Methods of Detoxification and Their Role in Treating Patients With Opioid Dependence
O'Connor
JAMA 2005;294:961-963.
FULL TEXT
Behavioral Therapies for Drug Abuse
Carroll and Onken
Am. J. Psychiatry 2005;162:1452-1460.
ABSTRACT
| FULL TEXT
Efficacy of Disulfiram and Cognitive Behavior Therapy in Cocaine-Dependent Outpatients: A Randomized Placebo-Controlled Trial
Carroll et al.
Arch Gen Psychiatry 2004;61:264-272.
ABSTRACT
| FULL TEXT
Evidence-Based Treatments for Substance Use Disorders
Gold and Brady
Focus 2003;1:115-122.
ABSTRACT
| FULL TEXT
Bridging the Gap: A Hybrid Model to Link Efficacy and Effectiveness Research in Substance Abuse Treatment
Carroll and Rounsaville
Psychiatr. Serv. 2003;54:333-339.
ABSTRACT
| FULL TEXT
Other Articles Noted
Evid. Based Ment. Health 2002;5:40-40.
FULL TEXT
|
